Page last updated: 2024-12-09

meglumine iodipamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID636408
CHEMBL ID3989806
SCHEMBL ID180308
MeSH IDM0049480

Synonyms (50)

Synonym
methyl glucamine iodipamide
adipiodone meglumine
cavumbren
iodipamide methylglucamine salt
ultrabil
endocistobil
transbillix
intrablix
cholograf-n-methylglucamine
meglumine iodipamide
iodipamide meglumine salt
endographin
1-deoxy-1-(methylamino)-d-glucitol 3,3'-(adipoyldiimino)bis(2,4,6-triiodobenzoate) (2:1) (salt)
biligrafin forte
einecs 222-534-5
methyl glucamine biligrafin
endografin
iodipamide methylglucamine
glucitol, 1-deoxy-1-(methylamino)-, 3,3'-(adipoyldiimino)bis(2,4,6-triiodobenzoate)(2:1) (salt), d-
cholografin meglumine (tn)
D01916
iodipamide meglumine (usp)
methylglucamine iodipamide
x064o0y1a4 ,
adipiodone meglumine injection [jan]
adipiodone meglumine injection
unii-x064o0y1a4
iodipamide meglumine [usp]
iodipamide meglumine [vandf]
d-glucitol, 1-deoxy-1-(methylamino)-, 3,3'-((1,6-dioxo-1,6-hexanediyl)diimino)bis(2,4,6-triiodobenzoate) (2:1)
iodipamide meglumine [orange book]
intrabilix
sinografin component iodipamide meglumine
iodipamide meglumine [usp impurity]
iodipamide meglumine component of sinografin
iodipamide bis(n-methylglucamine) salt [mi]
iodipamide bis(n-methylglucamine) salt
adipiodone meglumine [who-dd]
bilipolinum
meglumine adipiodone [mart.]
SCHEMBL180308
meglumine adipiodone
iodipamide methylglucamine injection
CHEMBL3989806
Q27293152
iodipamide meglumine (usp impurity)
bis(1-deoxy-1-(methylazaniumyl)-d-glucitol) 3,3'-((1,6-dioxohexane-1,6-diyl)diimino)bis(2,4,6-triiodobenzoate)
benzoic acid, 3,3'-((1,6-dioxo-1,6-hexanediyl)diimino)bis(2,4,6-triiodo)-, compound with 1-deoxy-1-(methylamino)-d-glucitol(1:2)
glucitol, 1-deoxy-1-(methylamino)-, 3,3'-(adipoyldiimino)bis(2,4,6-triiodobenzoate)(2:1)(salt)
meglumine adipiodone (mart.)

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"To assess the stability of doxorubicin combined with Radioselectan."( Stability of doxorubicin combined with Radioselectan, a contrast agent, for chemoembolization.
Chiadmi, F; Cisternino, S; Daroso, J; Fontan, JE; Ratiney, R; Schlatter, J, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
radioopaque mediumA substance having the property of absorbing, and therefore being opaque to, electromagnetic radiation, particularly X-rays.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organoammonium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (139)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990125 (89.93)18.7374
1990's9 (6.47)18.2507
2000's3 (2.16)29.6817
2010's2 (1.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.01 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index4.07 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (2.61%)5.53%
Reviews2 (1.31%)6.00%
Case Studies5 (3.27%)4.05%
Observational0 (0.00%)0.25%
Other142 (92.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]